



15-153

158  
16/ Letter  
15/ re Jones  
030

PATENT APPLICATION  
DOCKET NO.: CRP-056

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Oppermann et al.  
Serial No.: 07/599,543  
Filed: October 18, 1990  
Title: OSTEOGENIC PROTEIN

*Witter*

RECEIVED  
JAN 24 1992  
GROUP 150

15X1

2-7-92

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Honorable  
Commissioner of Patents and Trademarks, Washington,  
D.C. 20231 on 1/16/92

*Robin E. Bolduc*  
Signature

1/16/92  
Date

**Notice to Comply with Requirements for  
Patent Applications Containing Nucleotide Sequence  
And/Or Amino Acid Sequence Disclosures**


The Honorable Commissioner  
of Patents and Trademarks  
Washington, D. C. 20231

Sir:

As a result of my conversation with Ms. Meredith Charak on  
December 17, 1991 and my conversations with both Ms. Charak and  
Ms. Dora Stroud on January 14, 1992, we understand that the  
Sequence Listing in computer readable form for this application,  
provided to the Patent Office on November 8, 1991 is in order,  
and complies with all requirements set forth in U.S. 37 §1.821-

1.825. Accordingly, the Notice to Comply mailed from the Patent Office on October 10, 1991 was responded to appropriately and we are disregarding the subsequent Notice mailed from the Patent Office on December 9, 1991. Moreover, as the Notice to Comply was responded to appropriately within the one-month deadline, we understand that no extension fees are due to maintain the pendency of this application.

Respectfully submitted,



Robin D. Kelley  
Patent Agent for Applicants  
Registration No. 34,637  
(617) 248-7000

Date: 01/16/92

53 State Street  
Boston, MA 02109

299RDK2054/23.AU4

EDMUND R. PITCHER  
TESTA, HURWITZ & THIBEAULT  
EXCHANGE PLACE  
53 STATE ST.  
BOSTON, MA 02109

07/5 1,543  
10/18/90  
HERMAN OPPERMANN

COPY

#15  
RECEIVED

JAN 24 1992



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES GROUP 150

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☐ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☐ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
  - ☐ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: \_\_\_\_\_
  - ☐ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
  - ☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: \_\_\_\_\_
  - ☐ d. Other: \_\_\_\_\_
- ☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
- ☐ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
- ☒ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically:  
*See Attached Raw Sequence Listing with errors.*
- ☐ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
- ☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
- ☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that on file. § 1.825(d). Specifically: \_\_\_\_\_
- ☐ 11. Other: \_\_\_\_\_

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the amendments will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extension time may be obtained by filing a petition accompanied by the extension fee under the 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the u copy of this notice MUST be returned with your response.

☒ *Bara Stroud*  
For: Manager, Application Processing Division

(703) 308.1202



Examining Group.  
(703) 308.